Henoch-Schönlein purpura complicating adalimumab therapy for Crohn’s disease

Farooq Z Rahman, Gagandeep K Takhar, Ovishek Roy, Anna Shepherd, Stuart L Bloom, Sara A McCartney

Abstract

Anti-tumour necrosis factor-α (TNF) therapy has revolutionised the management of chronic inflammatory conditions. With ever increasing numbers of patients being treated with these agents, uncommon adverse reactions will inevitably occur more frequently. Cutaneous manifestations are associated with many of these chronic conditions and can complicate anti-TNF therapy in about 20% of cases. Vasculitic complications are rarely associated with anti-TNF therapy. Henoch-Schönlein purpura (HSP), a small vessel vasculitis, has been described following infliximab and etanercept therapy but never with adalimumab, a fully humanized TNF antibody. The risk of such immune-mediated reactions is theoretically less with adalimumab compared to infliximab but can still occur. Here we report the first case in the literature of HSP that can be attributed to the use of adalimumab in a 19-year-old male with recalcitrant Crohn’s disease.

© 2010 Baishideng. All rights reserved.

Key words: Henoch-Schönlein purpura; Adalimumab; Anti-TNF therapy; Leukocytoclastic vasculitis; Crohn’s disease

Peer reviewers: Won Ho Kim, MD, Professor, Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon-dong Seodaemun-ku, Seoul 120-752, South Korea; Shmuel Odes, Professor, MD, Department of Gastroenterology and Hepatology, Soroka Medical Center, POBox 151, Beer Sheva 84101, Israel

Rahman FZ, Takhar GK, Roy O, Shepherd A, Bloom SL, McCartney SA. Henoch-Schönlein purpura complicating adalimumab therapy for Crohn’s disease. World J Gastrointest Pharmacol Ther 2010; 1(5): 119-122 Available from: URL: http://www.wjgnet.com/2150-5349/full/v1/i5/119.htm DOI: http://dx.doi.org/10.4292/wjgpt.v1.i5.119

INTRODUCTION

Anti-tumour necrosis factor-α (TNF) therapies have radically improved the management of chronic inflammatory conditions that are frequently associated with significant morbidity and a substantial burden to health service resources. These biologic agents are efficacious both for induction and long-term maintenance of remission in several conditions including; rheumatoid arthritis, ankylosing spondylitis, psoriasis and psoriatic arthritis, and the idiopathic inflammatory bowel diseases (Crohn’s disease (CD), ulcerative colitis). Anti-TNF agents can be broadly divided into neutralizing antibodies (infliximab, adalimumab, certolizumab) and recombinant receptors (etanercept). The neutralising antibodies are commonly used to treat patients with refractory, steroid-dependent, or fistulising CD. Adalimumab (HUMIRA, Abbott), marked in the UK for 6 years, is currently used primarily in those who have lost response to, or are unable to tolerate infliximab.

A number of cutaneous adverse events have been reported with anti-TNF therapy including; infusion and
injection site reactions, psoriatic eruptions, lupus-like disorders, vasculitis, granulomatous reactions, and cutaneous infections/neoplasms\cite{10,11}. Whilst infusion and injection site reactions are unquestionably related to administration of anti-TNF agents, all other events have a varying strength of association and severity, not necessarily requiring drug discontinuation. Eczematous/psoriatic eruptions and infections are the commonest cutaneous complications with vasculitic manifestations occurring less frequently\cite{12,13}. Henoch-Schönlein purpura (HSP), a small vessel vasculitis, is an extremely rare complication of anti-TNF therapy but has been described following infliximab\cite{14} and etanercept\cite{15,16} therapy. Although adalimumab is associated with various features of HSP there are no formal reports of adalimumab-induced HSP in the literature. The risk of such immune-mediated reactions is theoretically less with adalimumab, a fully humanized TNF antibody, compared to infliximab, a chimeric monoclonal antibody, but can still occur.

**CASE REPORT**

A 19-year-old male non-smoker with quiescent ileo-colonic and perianal CD on combination therapy with azathioprine (AZA) and fortnightly adalimumab, presented with a 10 d history of a purpuric rash on both legs and diffuse joint pain and swelling. These symptoms were preceded by a short-lived coryzal illness from which he had made a full recovery. There were no gastrointestinal symptoms of note. He had taken his most recent dose of adalimumab 2 d prior to developing the rash.

His CD, initially diagnosed in 1999, was not associated with any extra-gastrointestinal manifestations. Over the decade since diagnosis his CD had failed to respond to various established (5-aminosalicylates, AZA, methotrexate, infliximab) and experimental (natalizumab and leukocytapheresis (adacolumn)) medical therapies, and surgical interventions including a subtotal colectomy, ileal resection and ileostomy formation had been required. Adalimumab therapy was initiated 7 mo previously due to gumbling active disease on AZA monotherapy. The patient received a routine induction regimen with 160 mg at week 0 and 80 mg at week 2, and continued on a fortnightly maintenance dose of 40 mg. This was well tolerated achieving a prolonged remission.

On examination he was haemodynamically stable with a non-blanching purpuric rash on his lower limbs (Figure 1), marked synovitis and swelling of both hands and a tender swollen right elbow. There were no signs of meningism. The full blood count was normal apart from a mildly elevated eosinophil count of 0.44 × 10^9/L. The C-reactive protein (CRP) was 15.1 mg/L (normal range 0.4-10 mg/L) and erythrocyte sedimentation rate (ESR) 13 mm/h (normal range 1-5 mm/h). Urea and electrolytes and liver function tests were within normal limits and a chest x-ray and x-rays of the swollen joints were unremarkable. The total IgA was elevated at 4.38 g/L (normal range 0.5-3.5 g/L) with normal IgG and IgM levels. The results of other blood tests that were performed are shown in Table 1. Urinalysis showed proteinuria and numerous amorphous deposits but no casts, red or white cells. The total urine protein was 0.2. An ultrasound scan of the renal tract was normal. A skin biopsy was also taken under local anesthetic.

The patient remained systemically well and was managed conservatively in conjunction with the rheumatologists and nephrologists. After a few days the pain and joint swelling improved dramatically and the rash began to fade. The skin biopsy confirmed a leukocytoclastic vasculitis (Figure 2) consistent with the clinical diagnosis of HSP, although the precise aetiology was unclear (recent viral illness vs adalimumab). A multi-disciplinary decision was taken to commence a further trial of adalimumab, given the favorable response of his previously recalcitrant CD to treatment and a paucity of evidence linking it to HSP. After a repeat dose of adalimumab on the ward, which was well tolerated, he was discharged with outpatient follow-up.

He re-presented 3 d later with polyarthropathy and a florid vasculitic rash on his legs. Although he remained systemically well he was finding it difficult to weight bear due to pain in his knees and right ankle. Baseline investigations were again unremarkable apart from raised inflammatory markers (CRP 22.2 mg/L, ESR 8 mm/h) and serum IgA level. Urinalysis revealed proteinuria and microscopic haematuria. The right ankle was aspirated excluding septic and crystal arthropathy. He was treated with intra-articular (right ankle) and systemic steroids. His
symptoms rapidly improved and he was discharged home on a reducing dose of prednisolone. Adalimumab therapy was discontinued. His HSP-related symptoms completely resolved over the next few weeks and did not recur on completion of the course of steroids. Seven months later his CD is mildly active again on AZA monotherapy and he is being considered for a trial of a novel biological agent (anti-IL-12/23, ustekinumab) in CD.

**DISCUSSION**

HSP is a multi-system small vessel vasculitis, usually affecting children, which can be defined according to multiple classifications.[17] It commonly manifests with palpable purpura along with acute arthritis (typically involving the ankles, knees and elbows), enteritis and nephritis (causing haematuria and/or proteinuria). Neurological, pulmonary, cardiac and genitourinary complications occur rarely. The prognosis is generally favorable in children, where symptoms tend to last about 4 wk, resolving spontaneously. Adult onset is rare but associated with more severe manifestations and a poor prognosis.

Although the cause is unknown, HSP can develop after various viral and bacteria infections and as an idiosyncratic reaction to several drugs. IgA is thought to play central role in the immunopathogenesis. The rare association between HSP and CD is recognized but poorly understood.[18,19]

The diagnosis is based on the combination of symptoms, as very few other diseases cause the same symptoms together. There are no diagnostic laboratory investigations although platelet count, urea, creatinine, IgA (50%), CRP and ESR may be elevated. Histology typically shows a hypersensitivity vasculitis and immunofluorescence demonstrates IgA and C3 (complement system protein) in the blood vessel wall. Treatment is usually supportive and directed against the precipitating cause. Immunosuppressants and immunoglobulin infusions are occasionally required in serious cases.

There have been several prior reports of localised cutaneous adverse events, including necrotizing and leukocytoclastic vasculitis, with infliximab and etanercept.[20] Most cases of cutaneous vasculitis develop within 3 mo of initiating anti-TNF therapy. HSP complicating anti-TNF therapy appears to be rare. The Medicines and Health-care products Regulatory Agency (MHRA) has received one report each for etanercept and infliximab since 1999. In the literature there are two reports of HSP following etanercept[15,16] and one following infliximab.[14] It has not yet been associated with adalimumab although features of it such as vasculitic rash, arthralgia and glomerulonephritis have. Since January 2003 the MHRA has received 7 reports of vasculitic rash, 27 of arthralgia and 4 of glomerulonephritis for adalimumab. There is one case report of a cutaneous small vessel vasculitis and necrotizing crescentic glomerulonephritis in an anti-neutrophil cytoplasmic antibody positive patient that resolved on withdrawal of adalimumab and immunosuppressive therapy.[21] It is possible that some of these reactions may have been manifestations of undiagnosed HSP.

Here we describe the first case of adalimumab-associated HSP occurring after 7 mo of treatment for CD.
Discontinuation of the drug and treatment with systemic steroids led to the complete resolution of the vasculitis and polyarthropathy. HSP has now been described with all three commonly used anti-TNF agents - and occurred after several months of anti-TNF therapy in all cases. Thus HSP or features of it, occurring during chronic use of these biologics must be considered as possibly related to the therapy. HSP manifests more severely and is associated with a worse prognosis in adults. Renal involvement, a key discriminator of long-term outcome, is more common in this group. It has been reported that up to one third of HSP patients with renal involvement eventually progress to end stage renal failure. Given that the use of anti-TNF therapies is likely to increase further in the future, prescribers need to be aware of this potentially serious complication.

REFERENCES

1. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10: iii-iv, xi-xiii, 1-229
2. McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dunbar Y, Hill RA, Jones A, Mujica Mota R, Walley T. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-158, iii-iv
3. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005; 19: 47-57
4. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035
5. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549
6. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333; quiz 591
7. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65
8. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238
9. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanss J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476
10. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segar! S, Hendkaerts L, Van Assche G, Vermeire S, Rutgeerts P. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Curr 2009; 58: 501-508
11. Lee IH, Song HJ, Friedrich M, Gauliard M, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Wom M. Cutaaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156: 486-491
12. Saint Marcoux B, De Bandt M. Vasculitides induced by TNF-alpha inhibitors: a study in 39 patients in France. Joint Bone Spine 2006; 73: 710-713
13. Ramos-Casals M, Brito-Zerón P, Cuadrado MJ, Khamashia MA. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep 2008; 10: 442-448
14. Nobile S, Catassi C, Felici L. Herpes zoster infection followed by Henoch-Schönlein purpura in a girl receiving infliximab for ulcerative colitis. J Clin Rheumatol 2009; 15: 101
15. Lee A, Kasama R, Evangelisto A, Ellenstein B, Falasca G. Henoch-Schönlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol 2006; 12: 249-251
16. Duffy TN, Genta M, Moll S, Martin PY, Gabay C. Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: S106
17. Saulsbury FT. Henoch-Schönlein purpura. Curr Opin Rheumatol 2001; 13: 35-40
18. Cassater D, Gambaro F, Fabris A, Cena C, Calabria S, Capeluto S, Lupo A. Henoch-Schönlein purpura and Crohn's disease in a family. J Nephrol 2006; 19: 387-391
19. Saulsbury FT, Hart MH. Crohn's disease presenting with Henoch-Schönlein purpura. J Pediatr Gastroenterol Nutr 2000; 31: 173-175
20. Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel JN, Braun MM. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004; 31: 1955-1958
21. Simms R, Kippen D, Dahill S, Marshall D, Rodger RS. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis 2008; 51: e11-e14
22. Saulsbury FT. Clinical update: Henoch-Schönlein purpura. Lancet 2007; 369: 976-978

S-Editor Wang JL  L-Editor Hughes D  E-Editor Yang C